Pieris Pharmaceuticals, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, has appointed James Geraghty to its Board of Directors, bringing the total number of directors to eight.
Geraghty is an industry leader with 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercialising therapies.
Until 2016, Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund. He previously served as Senior Vice President, North America Strategy and Business Development at Sanofi, which he joined upon its acquisition of Genzyme.
Geraghty spent 20 years at Genzyme, where his roles included Senior Vice President International Development, President of Genzyme Europe, and General Manager of Genzyme's cardiovascular business.
Geraghty also oversaw Genzyme's Humanitarian Assistance for Neglected Diseases (HAND) programme, under which the company supported development programmes on a non-commercial basis.
Geraghty is Chair of the Board of Idera Pharmaceuticals and Juniper Pharmaceuticals and serves on the Board of Voyager Therapeutics and Fulcrum Therapeutics. He is also a member of the BIO Ventures for Global Health Board of Directors.
He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, Geraghty holds a MS from the University of Pennsylvania and a BA from Georgetown University.